

JAN 16 2003

Sheet 1 of 1

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
B45158SERIAL NO.
09/807,657

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Nathalie GarconFILING DATE
16 April 2001GROUP
1648

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

32	CA	ImmunEasy Mouse Adjuvant Handbook, Qiagen Worldwide, pp. 1-20. June 2002.
32	CB	Weeratna, et al., "CpG DNA Induces Stronger Immune Responses with Less Toxicity than Other Adjuvants", <i>Vaccine</i> , <u>18</u> : 1755 (2000).
32	CC	Davis, et al., "CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen", <i>J. Immunology</i> , <u>160</u> : 870 (1998). (Published Erratum appears in <i>J. Immunology</i> , <u>162</u> : 3103 (1999).
32	CD	Lipford, et al., "CpG-Containing Synthetic Oligonucleotides Promote B and Cytotoxic T Cell Responses to Protein Antigen: A New Class of Vaccine Adjuvants", <i>Eur. J. Immunol.</i> , <u>27</u> : 2340 (1997).
42	CE	Krieg, et al., "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation", <i>Nature</i> , <u>374</u> : 546 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\avi\patapps\b45158\pto 1449 form.doc